PURPOSE: Describe the incidence and identify risk factors for seroma development after MammoSite breast brachytherapy (MBT). METHODS AND MATERIALS: MBT patient data were prospectively recorded into a quality assurance database. Departmental and electronic records were reviewed to extract patient-, treatment-, and outcome-specific data. Stepwise logistic regression analysis was performed to identify factors associated with development of any seroma including the subset of clinically significant seroma (CSS). CSS was defined as a symptomatic seroma requiring multiple aspirations, biopsy, and/or excision. Variables analyzed included age, weight, number of excisions, time from resection to catheter placement, placement technique, balloon volume, dosimetric factors, and postbrachytherapy infection. RESULTS: MBT was performed in 109 patients, of whom 97 had minimum 6 months (median, 36) post-MBT follow-up or earlier development of seroma. All patients received 34 Gy to 1cm depth from balloon surface, delivered twice daily in 10 fractions. Seroma developed in 41% of patients at a median of 3 months (range, 0.1-25) post-MBT. One-third of seromas (13% of all patients) were CSS. The only factor identified as statistically significant for development of any seroma was catheter placement on day of resection vs. > or =1 day later (59% vs. 33%; p = 0.0066). Post-MBT infection was highly statistically significant for development of CSS (64% vs. 7%; p<0.0001). Prophylactic antibiotics reduced the risk of post-MBT infection from 37.5% to 6% (p = 0.011). CONCLUSIONS: The incidence of CSS after MBT is low. Post-MBT infection is statistically significantly associated with CSS development, the incidence of which is reduced with prophylactic antibiotics.
PURPOSE: Describe the incidence and identify risk factors for seroma development after MammoSite breast brachytherapy (MBT). METHODS AND MATERIALS: MBT patient data were prospectively recorded into a quality assurance database. Departmental and electronic records were reviewed to extract patient-, treatment-, and outcome-specific data. Stepwise logistic regression analysis was performed to identify factors associated with development of any seroma including the subset of clinically significant seroma (CSS). CSS was defined as a symptomatic seroma requiring multiple aspirations, biopsy, and/or excision. Variables analyzed included age, weight, number of excisions, time from resection to catheter placement, placement technique, balloon volume, dosimetric factors, and postbrachytherapy infection. RESULTS: MBT was performed in 109 patients, of whom 97 had minimum 6 months (median, 36) post-MBT follow-up or earlier development of seroma. All patients received 34 Gy to 1cm depth from balloon surface, delivered twice daily in 10 fractions. Seroma developed in 41% of patients at a median of 3 months (range, 0.1-25) post-MBT. One-third of seromas (13% of all patients) were CSS. The only factor identified as statistically significant for development of any seroma was catheter placement on day of resection vs. > or =1 day later (59% vs. 33%; p = 0.0066). Post-MBT infection was highly statistically significant for development of CSS (64% vs. 7%; p<0.0001). Prophylactic antibiotics reduced the risk of post-MBT infection from 37.5% to 6% (p = 0.011). CONCLUSIONS: The incidence of CSS after MBT is low. Post-MBT infection is statistically significantly associated with CSS development, the incidence of which is reduced with prophylactic antibiotics.
Authors: Pamela R Benitez; Oscar Streeter; Frank Vicini; Vivek Mehta; Coral Quiet; Robert Kuske; Mary Katherine Hayes; Doug Arthur; Henry Kuerer; Gary Freedman; Martin Keisch; Thomas Dipetrillo; David Khan; Richard Hudes Journal: Am J Surg Date: 2006-10 Impact factor: 2.565
Authors: Peter Niehoff; Csaba Polgár; Horst Ostertag; Tibor Major; Zoltán Sulyok; Bernhard Kimmig; György Kovács Journal: Radiother Oncol Date: 2006-06-14 Impact factor: 6.280
Authors: Victor Zannis; Peter Beitsch; Frank Vicini; Coral Quiet; Angela Keleher; Delia Garcia; Howard Snider; Mark Gittleman; Henry Kuerer; Eric Whitacre; Patrick Whitworth; Richard Fine; Bruce Haffty; Alan Stolier; John Mabie Journal: Am J Surg Date: 2005-10 Impact factor: 2.565
Authors: Pamela R Benitez; Martin E Keisch; Frank Vicini; Alan Stolier; Troy Scroggins; Alonzo Walker; Julia White; Peter Hedberg; Mary Hebert; Doug Arthur; Vic Zannis; Coral Quiet; Oscar Streeter; Mel Silverstein Journal: Am J Surg Date: 2007-10 Impact factor: 2.565
Authors: Suzanne B Evans; Seth A Kaufman; Lori Lyn Price; Gene Cardarelli; Thomas A Dipetrillo; David E Wazer Journal: Int J Radiat Oncol Biol Phys Date: 2006-03-20 Impact factor: 7.038
Authors: D E Wazer; T DiPetrillo; R Schmidt-Ullrich; L Weld; T J Smith; D J Marchant; N J Robert Journal: J Clin Oncol Date: 1992-03 Impact factor: 44.544
Authors: Jacqueline S Jeruss; Henry M Kuerer; Peter D Beitsch; Frank A Vicini; Martin Keisch Journal: Ann Surg Oncol Date: 2010-06-25 Impact factor: 5.344